

1 **Article title: “Clinical, Radiological and Therapeutic Characteristics of Patients with COVID-**
2 **19 in Saudi Arabia”**

3 **Authors’ names:**

4 Mohammed Shabrawishi, M.D,^{1,2} Manal M Al-Gethamy, M.D,³ Abdallah Y Naser, PhD,⁴ Maher A Ghazawi,
5 M.D,⁵ Ghaidaa F Alsharif, M.D,² Elaf F Obaid, M.D,² Haitham A Melebari, M.D,⁶ Dhaffer M Alamri,³ Ahmad
6 S Brinji, M.D,⁵ Fawaz H Al Jehani, M.D,⁷ Wail Almaimani, M.D,⁷ Rakan A Ekram, M.D,⁸ Kasim H Alkhatib,
7 M.D,⁹ Hassan Alwafi, M.D¹⁰

8 **Authors affiliations:**

9 ¹Department of Respiratory Medicine, Al Noor Specialist Hospital, Mecca, Saudi Arabia.

10 ²Department of Internal Medicine, Al Noor Specialist Hospital, Mecca, Saudi Arabia.

11 ³Department of Infection Prevention and Control Programme, Al Noor Specialist Hospital, Mecca, Saudi
12 Arabia.

13 ⁴Faculty of Pharmacy, Isra University, Amman, Jordan.

14 ⁵Department of Radiology, Al Noor Specialist Hospital, Mecca, Saudi Arabia.

15 ⁶Department of Internal Medicine, King Faisal General Hospital, Mecca, Saudi Arabia.

16 ⁷Al Noor Specialist Hospital, Mecca, Saudi Arabia.

17 ⁸School of Public Health and Health Informatics, Umm Al Qura University, Mecca, Saudi Arabia.

18 ⁹Intensive Care Department, Al Noor Specialist Hospital, Mecca, Saudi Arabia.

19 ¹⁰Department of Clinical Pharmacology and Toxicology, Faculty of Medicine, Umm Al Qura University,
20 Mecca, Saudi Arabia.

21

22 **Corresponding author**

23 Dr.Hassan Alwafi

24 Department of Clinical Pharmacology and Toxicology

25 Umm Alqura University, Faculty of Medicine

26 Mecca, Saudi Arabia

27 Post Code 24381

28 T +966555544319

29 Email: hwafi@uqu.edu.sa

30 Number of words in abstract: 249 words

31 Number of words in main body text: 2,633 words

32 Number of tables in main body text: 4 table

33 Number of figures in main body text: 3 figures

34 Number of references in main body text: 34

35 **Abstract (249)**

36 **BACKGROUND**

37 Coronavirus disease 2019 (COVID-19) is a rapidly spreading global pandemic. The clinical
38 characteristics of COVID-19 has been reported; however, there are limited researches that
39 investigated the clinical characteristics of COVID-19 in the Middle East. The aim of this study is to
40 investigate the clinical, radiological and therapeutic characteristics of patients diagnosed with
41 COVID19 in Saudi Arabia.

42 **METHODS**

43 This study is a retrospective single-centre case series study. We extracted data for patients who were
44 admitted to the Al-Noor Specialist hospital with a PCR confirmed SARS-COV-2 between 12th and
45 31st of March 2020. Descriptive statistics were used to describe patients' characteristics. Continuous
46 data were reported as mean \pm SD. Chi-squared test/Fisher test were used as appropriate to compare
47 proportions for categorical variables.

48 **RESULTS**

49 A total of 150 patients were hospitalised for COVID-19 during the study period. The mean age was
50 46.1 years (SD: 15.3 years). Around 61.0% (n= 90) were males and six patients (3.9%) reported
51 working in the healthcare sector. The most common comorbidities were hypertension (28.8%, n= 42)
52 and diabetes mellitus (26.0%, n= 38). The majority of the patients, 64.4% (n = 96) had a recent
53 contact history with a COVID patient. Regarding the severity of the hospitalised patients, 105 patients
54 (70.0%) were mild, 29 (19.3%) were moderate, and 16 patients (10.7%) were severe or required ICU
55 care. From the 105 mild patients, around 31.3% (n= 47) were asymptomatic.

56 **CONCLUSION**

57 This case series provides clinical, radiological and therapeutic characteristics of hospitalised patients
58 with confirmed COVID-19 in Saudi Arabia.

59 **KEYWORDS**

60 Clinical Characteristics, COVID-19, Retrospective case series, Radiological SARS-Cov2

61

62 1. INTRODUCTION

63 In early December 2019, a cluster of acute pneumonia of unknown aetiology has been identified in
64 Wuhan, China (1). The pathogen has been identified as a new RNA virus from the betacoronavirus
65 family, and has been named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (2).
66 The respiratory illness caused by the 2019 novel coronavirus disease (COVID-19) is highly
67 infectious, and therefore, the World Health Organization (WHO) has characterized the diseases a
68 pandemic infection (3). As of April 25, 2020, more than 2,700,000 confirmed cases were reported
69 worldwide, and it has spread from Wuhan to more than 200 countries across the world (4).

70 The Kingdom of Saudi Arabia (KSA) is the largest country in the Arabian Peninsula and it is located
71 in the South West part of Asia (5). In a historical decision, KSA has suspended Umrah and all
72 religious visits to the country in an attempt to prevent and delay the spread of COVID-19 in KSA.
73 However, in March 2, 2020, Saudi Arabia has confirmed its first case of COVID-19 which was
74 imported from Iran (4). Several other local clusters were identified later with the majority of the cases
75 being linked to recent travel history.

76 In recent studies, the clinical features and severity of COVID-19 has been described to be similar of
77 other respiratory viruses such as severe acute respiratory syndrome (SARS) and Middle East
78 respiratory syndrome (MERS) (6, 7). Symptoms can range from mild flu-like symptoms to acute
79 respiratory distress syndrome (ARDS) (8). However, the characteristics and the course of the disease
80 in Middle Eastern populations remains unclear. Exploring the clinical characteristics of patients
81 diagnosed with COVID-19 in Saudi Arabia is important knowing that there are many visitors who
82 travel to Saudi Arabia for religious purposes. Beside this, there is a high air traffic for other purposes
83 in this country which was estimated to be around 39 million people in 2018. In 2019, around 7.5
84 million Muslim entered the holy city of Mecca for Umrah purposes (9). This highlights how crucial is
85 to have a deeper exploration on the characteristics of patients diagnosed with this widespread
86 infection in this region. To address the above knowledge gaps and giving the ongoing spread of
87 COVID-19 in the Middle East, this study aims to describe the clinical, radiological, and therapeutic
88 characteristics of COVID-19 in a selected cohort of patients in Mecca, Saudi Arabia.

89 2. METHODS

90 2.1. Study Design and participants

91 This was a retrospective single-centre case series study of 150 patients diagnosed with COVID-19.
92 We extracted data for patients who were admitted to Al-Noor Specialist hospital with a polymerase
93 chain reaction (PCR) confirmed SARS-COV-2 between 12th and 31st of March 2020. Al-Noor
94 Specialist hospital in Mecca, Saudi Arabia is a 500-bedder specialist and teaching hospital in the
95 centre of the holy city of Mecca. It delivers tertiary care throughout the Mecca region of Saudi Arabia

96 and its part of the Ministry of Health services (10, 11). All patients enrolled in this study were
97 diagnosed with COVID-19 through real time (RT)-PCR obtained through nasopharyngeal swabs. All
98 data including outcomes, mortality and length of stay were monitored up to 8th April 2020.

99 **2.2. Data Collection**

100 Data were extracted from both paper and electronic records using a unique medical record number
101 (MRN) for each patient. All data were reviewed and checked by a medical team including; two
102 medical residents and a consultant Pulmonologist. Extracted data included patients' demographics,
103 comorbidities, history of recent travel and history of contact with a confirmed COVID19 patient in the
104 past two weeks. In addition, clinical signs, symptoms, radiological findings and pharmacological
105 treatment received were collected. The radiological examinations were interpreted by a certified
106 consultant radiologist who was blinded from the clinical presentation of the patients. The severity
107 assessment of the chest x-ray (CXR) were estimated subjectively. All data were collected at the time
108 of the admission.

109 **2.3. Study variables**

110 Data regarding the clinical progression and severity of the disease were reported as the worst
111 classification reached at any point during hospitalisation. We further classified the severity of the
112 disease based on the following criteria; 1) mild disease was defined as patients with upper respiratory
113 tract symptoms (as rhinorrhoea, sore throat, headache, myalgia, body pain, low grade fever and or dry
114 cough) with absent of clinical or radiological finding of pneumonia; 2) moderate disease defined as
115 symptomatic patients with radiological sign of pneumonia; 3) severe disease defined as confirmed
116 COVID-19 pneumonia with any of the following respiratory rate ≥ 30 /min, blood oxygen saturation
117 $\leq 93\%$ at rest, PaO₂/FiO₂ ratio < 300 , lung infiltration $> 50\%$ of the lung field, and 4) critically severe
118 disease defined as any of the following: respiratory failure required invasive mechanical ventilation,
119 shock or organ failure require admission to the intensive care unit.

120 **2.4. Ethics**

121 This study was approved by the institutional ethics board at the Ministry of Health in Saudi Arabia
122 (No. H-02-K-076-0420-286). Patients were informed that their clinical data will be used for clinical or
123 research purposes with keeping all their personal information confidential.

124 **2.5. Statistical Analysis**

125 Descriptive statistics were used to describe patients' demographic characteristics, radiological
126 findings, medications use, and comorbidities. Continuous data were reported as mean \pm SD, and
127 categorical data were reported as percentages (frequencies). Independent sample t test was used to

128 compare the mean value for continuous variables. Chi-squared test/Fisher test were used as
129 appropriate to compare proportions for categorical variables. Logistic regression analysis was used to
130 identify predictors of clinical characteristics. A confidence interval of 95% ($p < 0.05$) was applied to
131 represent the statistical significance of the results and the level of significance was assigned as 5%.
132 SPSS (Statistical Package for the Social Sciences) version 25.0 software (SPSS Inc) was used to
133 perform all statistical analysis.

134 3. RESULTS

135 3.1. Patients clinical characteristics

136 **Table 1** presents patients' characteristics at presentation to the hospital. A total of 150 patients were
137 hospitalised for COVID-19. The mean age was 46.1 years (SD: 15.3 years), and ranged between 11
138 and 87. Around 61.0% (n= 90) were males. Six patients (3.9%) reported working in the healthcare
139 sector. The most common comorbidities were hypertension (28.8%, n= 42) and diabetes mellitus
140 (DM) (26.0%, n= 38). The majority of the patients (56.0%; n= 84) were local resident. Around half of
141 the patients (54.1%, n= 80) reported that they had a contact history with a traveller. In addition, the
142 majority of the patients, 64.4% (n = 96) had a contact history with a COVID-19 patient. Regarding the
143 severity of the hospitalised patients, 105 patients (70.0%) were mild, 29 (19.3%) were moderate, and
144 16 patients (10.7%) were severe or required ICU care. Of the 105 mild patients, around 31.3% (n= 47)
145 were asymptomatic. Patients with comorbidities were more likely to have a severe outcome compared
146 to other patients ($p < 0.05$). Patients who reported a contact history with a COVID-19 patient were
147 more likely to have mild to moderate severity of the disease ($p < 0.05$). Mild cases were more prevalent
148 among females, while moderate to severe and or critical were prevalent among males (**Figure 1**). For
149 symptomatic patients, the most common symptoms at presentation were fever (49.3%, n= 72), dry
150 cough (48.6%, n= 71), and shortness of breath (19.9%, n= 29) (**Table 2**). Furthermore, during
151 admission, fever and cough (28%) were the most common symptoms followed by nausea and
152 vomiting (12%). Most of the asymptomatic patients were females (OR: 0.45 [95%CI 0.22 – 0.92]; $p =$
153 0.027). In addition, patients who reported travel history or a contact with a traveller recently were
154 three times (OR: 3.13 [95%CI 1.52 – 6.45]; $p = 0.002$) and four times (OR: 4.03 [95%CI 1.84 – 8.81];
155 $p = 0.000$) more likely to be asymptomatic, respectively. Besides, patients who have reported a contact
156 with COVID-19 patients were four times at higher risk of being symptomatic (OR: 4.50 [95%CI 1.84
157 – 10.99]; $p = 0.001$).

158 3.2. Radiological findings

159 Around half of the patients (49.7%, n= 72) had normal radiological exam at presentation. The severity
160 of the cases was correlated with an increase in the prevalence of GGO at presentation ($P = 0.002$). The
161 predominant pattern of abnormality observed was ground-glass opacification (29.0%, n= 42),

162 peripheral (57.5%, n= 42), and (bilateral (35.3%, n= 35), which was mainly involving the lower lobes
163 (Figure 2). Most of the patients had stable radiological exams on follow up. Around 64.6% (n= 62)
164 showed progression, half of them belongs to more severe group (**Table 3**).

165 **3.3. Recovery**

166 Patients stayed at the hospital for a mean duration of 9.2 days (SD: 3.9). Duration of stay in hospital
167 ranged from two days to 23 days. At the end of the follow-up period a total of 94 patients (63.5%)
168 recovered and 31.8% (n= 47) improved clinically but RT-PCR results were still positive. On the other
169 hand, three patients (2.0%) did not fully recover and four patients (2.7%) deceased. There was no
170 statistically significant difference based on the age regarding the recovery or whether the patient was
171 symptomatic or asymptomatic upon presentation to hospital ($p>0.05$). The majority of the patients
172 with mild cases improved or recovered, however, there was no statistically significant difference
173 between cases from different severity and recovery rate ($p>0.05$) (**Figure 3**).

174 **3.4. Therapeutic management**

175 Beside supportive care, there were three main types of therapies that were prescribed to the patients
176 for the management of COVID-19, this includes: a) antiviral therapy, b) antibiotics, and c)
177 antimalarial medications (**Table 4**).

178 **4. DISCUSSION**

179 To the best of our knowledge, this is the first and largest study to examine the clinical characteristics
180 of COVID-19 in the Middle East region. We investigated clinical, radiological, and therapeutic
181 characteristics of COVID-19 in a 150 hospitalised patients in Saudi Arabia. We found that around
182 89.0% of the cases were either mild or moderated and only 11.0% were either severe or critical. Our
183 finding showed that the clinical severity of COVID-19 were of a milder presentation compared to
184 results from China (12), Italy (13) and the United States (14, 15). These finding could be attributed to
185 several factors including age and other demographics differences. The mean age in our study was 46.1
186 years (SD: 15.3) which was younger than the age reported in other studies. Several studies have
187 reported poorer outcome among older population and patients with COVID-19 and comorbidities (16-
188 18). However, it is difficult to draw a causal inference and we urge for further studies to investigate
189 this association. In addition, it is important to highlight that the majority of the Saudi Arabian
190 population are younger than 44 years (19).

191 Male patients with COVID-19 were more prevalent in our study compared to females, this was also
192 similar to previous reports which highlight more males to be infected with COVID-19 (2, 14). These
193 numbers could be because of men sex-based immunological differences or it could also be because of
194 behavioural patterns such as smoking (20). In addition, comorbidities are more prevalent in men

195 which could also be a reason for this difference (21), However, more researches must focus on gender
196 differences and clinical outcomes with COVID-19.

197 Our study highlighted that around 28.8% and 26.0% of the study population had hypertension (HTN)
198 and DM, these results were similar to previous reports that investigated the clinical characteristics of
199 COVID-19 (1). Patients with DM and hypertension have an increased risk of complication of
200 COVID-19 including acute respiratory distress syndrome (ARDS) (22), however, the mechanism of
201 this remains un-investigated and it is unclear whether patients with uncontrolled blood pressure have a
202 poorer outcomes of COVID-19 compared to patients with controlled blood pressure. In addition,
203 Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are two
204 commonly prescribed medications for the management of HTN, and since SARS-CoV-2, binds to
205 ACE2 in the lung, some theoretical theories have been raised about the benefits of these medications
206 in the treatment of COVID-19 (23).

207 SARS-COV2 has been described to be similar to seasonal influenza, SARS-COV and MERS, this
208 includes the fact that it is transmitted through respiratory droplets (24, 25). In addition, SARS-COV2
209 has similar symptoms to SARS-COV and MERS such as; fever, cough, and shortness of breath. This
210 was reported in our study and it was also in line with previous studies (6, 13), however, SARS-COV2
211 has a higher case fatality rate in comparison to seasonal flu (0.1%) while it is also milder in
212 comparison to other respiratory viruses such as SARS-COV (9.5%) and MERS (34.3%) (26). Besides
213 this, COVID-19 is a highly infectious pathogenic (27, 28), with some reports suggested that half of
214 the United Kingdom (UK) population has been infected without showing any symptoms or with
215 having a mild course of the disease (29). Our study demonstrated that around 31.3% of the study
216 sample were asymptomatic and had a mild disease. Mostly, these patients were identified through
217 contact tracing and were isolated in the earlier course of the disease, whether this approach have any
218 impact on the clinical course psychologically, this might need to be addressed in future studies. In
219 addition, the majority of these patients had a contact with a confirmed COVID-19 patients which may
220 raise concerns regarding the mechanism and the underlying inflammatory response in these patients.
221 More researches are encouraged to investigate the characteristics of asymptomatic patients and if
222 early detection and supportive treatment have a role in the clinical progression of the disease.

223 In our study, and unlike previous reports, nearly half of the patients presented with normal CXR, most
224 of them were asymptomatic or had a mild disease. Furthermore, normal CXR at presentation may
225 have a prognostic rule as only few numbers of those patients progressed into more severe cases. On
226 the other hand, presence of ground glass opacity is linked with more aggressive course. The patterns
227 found in abnormal exams were similar to the previously published reports and findings where
228 peripheral, bilateral ground glass opacification (30).

229 Our study highlighted that around 26.7% of the patients received antimalarial treatment and around
230 9.0% received antiviral treatment, these medications have been suggested to have some beneficial
231 effect to reduce the viral load and eliminate the disease, however, there are also uncertainties

232 regarding their safety (31, 32). In addition, there has been debate about their efficacy in the treatment
233 of COVID-19 with several trials are now in pipeline for the testing of these medications (33). To date,
234 there is no treatment for COVID-19, and the main approach in the management of the disease is to
235 provide supportive treatment and to control the symptoms including mechanical ventilator for critical
236 cases (34). This study has some limitations. First, the number of patients included in the study were
237 small. Second, the study population only included patients from a single-centre hospital in Saudi
238 Arabia.

239 **5. CONCLUSION**

240 This case series provides clinical, radiological, and therapeutic characteristics of hospitalised patients
241 with confirmed COVID-19 in Saudi Arabia. Our study demonstrates similar characteristics of
242 COVID-19 to previously reported studies worldwide.

243 **Conflict of interest**

244 The authors have stated explicitly that there are no conflicts of interest in connection with this article.

245 **Authors contribution**

246 Shabrawishi, Naser, Ghazawi and Alwafi had full access to all the data in the study and take
247 responsibility for the integrity of the data and the accuracy of the data analysis. Shabrawishi and
248 Alwafi had the original idea for this study. Shabrawishi, Naser and Alwafi contributed to the design of
249 the study. Obaid and Alsharif contributed to the data collection. Naser and Alwafi contributed in the
250 statistical analysis. Shabrawishi, Naser, Ekram and Alwafi wrote the first draft. All the authors
251 contributed to interpretation and edited the draft report.

252 **Data availability statement**

253 The data that support the findings of this study are available from the corresponding author upon reasonable
254 request.

255 **References:**

- 256 1. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized
257 Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*.
258 2020;323(11):1061-9.
- 259 2. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical Characteristics of Coronavirus
260 Disease 2019 in China. 2020.
- 261 3. WHO. Coronavirus disease 2019 (COVID-19) Situation Report –96 2020 [Available from:
262 [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200425-sitrep-96-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200425-sitrep-96-covid-19.pdf?sfvrsn=a33836bb_2)
263 [covid-19.pdf?sfvrsn=a33836bb_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200425-sitrep-96-covid-19.pdf?sfvrsn=a33836bb_2).
- 264 4. Who. Coronavirus disease (COVID-19) outbreak 2020 [Available from:
265 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>.

- 266 5. MOFA. About Saudi Arabia 2020 [Available from:
267 <https://www.mofa.gov.sa/sites/mofaen/aboutKingDom/Pages/KingdomGeography46466.aspx>.
- 268 6. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical
269 characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive
270 study. *Lancet* (London, England). 2020;395(10223):507-13.
- 271 7. Livingston E, Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy. *JAMA*. 2020.
- 272 8. Chang D, Lin M, Wei L, Xie L, Zhu G, Dela Cruz CS, et al. Epidemiologic and Clinical
273 Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China. *JAMA*.
274 2020;323(11):1092-3.
- 275 9. Ebrahim SH, Memish ZA. COVID-19: preparing for superspreader potential among Umrah
276 pilgrims to Saudi Arabia. *The Lancet*. 2020;395(10227).
- 277 10. Zaglool DA, Khodari YA, Gazzaz ZJ, Dhafar KO, Shaker HA, Farooq MU. Prevalence of
278 Intestinal Parasites among Patients of Al-Noor Specialist Hospital, Makkah, Saudi Arabia. *Oman Med*
279 *J*. 2011;26(3):182-5.
- 280 11. Health Mo. Al Noor Specialist Hospital 2020 [Available from:
281 <http://nsh.med.sa/Pages/Home.aspx>.
- 282 12. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus
283 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72,314 Cases From the Chinese
284 Center for Disease Control and Prevention. *JAMA*. 2020;323(13):1239-42.
- 285 13. Livingston E, Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy. *JAMA*.
286 2020;323(14):1335-.
- 287 14. Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical Characteristics of
288 Covid-19 in New York City. 2020.
- 289 15. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al.
290 Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With
291 COVID-19 in the New York City Area. *JAMA*. 2020.
- 292 16. Mahase E. Covid-19: death rate is 0.66% and increases with age, study estimates.
293 2020;369:m1327.
- 294 17. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity
295 of coronavirus disease 2019: a model-based analysis. *The Lancet Infectious diseases*. 2020.
- 296 18. Dowd JB, Andriano L, Brazel DM, Rotondi V, Block P, Ding X, et al. Demographic science aids
297 in understanding the spread and fatality rates of COVID-19. 2020:202004911.
- 298 19. Statistics Gaf. Statistical Yearbook of 2016 2016 [Available from:
299 <https://www.stats.gov.sa/en/5305>.
- 300 20. Wenham C, Smith J, Morgan R. COVID-19: the gendered impacts of the outbreak. *Lancet*
301 (London, England). 2020;395(10227):846-8.
- 302 21. The L. The gendered dimensions of COVID-19. *Lancet* (London, England).
303 2020;395(10231):1168.
- 304 22. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at
305 increased risk for COVID-19 infection? *The Lancet Respiratory medicine*. 2020;8(4):e21.
- 306 23. Schiffrin EL, Flack JM, Ito S, Muntner P, Webb RC. Hypertension and COVID-19. *American*
307 *Journal of Hypertension*. 2020.
- 308 24. Otter JA, Donskey C, Yezli S, Douthwaite S, Goldenberg SD, Weber DJ. Transmission of SARS
309 and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface
310 contamination. *The Journal of hospital infection*. 2016;92(3):235-50.
- 311 25. WHO. Modes of transmission of virus causing COVID-19: implications for IPC precaution
312 recommendations 2020 [Available from: [https://www.who.int/publications-detail/modes-of-](https://www.who.int/publications-detail/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations)
313 [transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations](https://www.who.int/publications-detail/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations).
- 314 26. Rajgor DD, Lee MH, Archuleta S, Bagdasarian N, Quek SC. The many estimates of the COVID-
315 19 case fatality rate. *The Lancet Infectious diseases*. 2020.

- 316 27. Zhang S, Diao M, Yu W, Pei L, Lin Z, Chen D. Estimation of the reproductive number of novel
 317 coronavirus (COVID-19) and the probable outbreak size on the Diamond Princess cruise ship: A data-
 318 driven analysis. *International journal of infectious diseases : IJID : official publication of the*
 319 *International Society for Infectious Diseases.* 2020;93:201-4.
- 320 28. Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher
 321 compared to SARS coronavirus. *Journal of Travel Medicine.* 2020;27(2).
- 322 29. Sayburn A. Covid-19: experts question analysis suggesting half UK population has been
 323 infected. 2020;368:m1216.
- 324 30. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with
 325 COVID-19 pneumonia in Wuhan, China: a descriptive study. *The Lancet Infectious Diseases.*
 326 2020;20(4):425-34.
- 327 31. Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. 2020;369:m1432.
- 328 32. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the
 329 efficacy and safety of chloroquine for the treatment of COVID-19. *Journal of critical care.* 2020.
- 330 33. Taccone FS, Gorham J, Vincent JL. Hydroxychloroquine in the management of critically ill
 331 patients with COVID-19: the need for an evidence base. *The Lancet Respiratory medicine.* 2020.
- 332 34. NICE. COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in
 333 the community 2020 [Available from: <https://www.nice.org.uk/guidance/ng165>].

334 TABLES LEGENDS

335 Table 1: Patients demographic characteristics at presentation.

336 Table 2: Patient signs and symptoms at presentation and during admission.

337 Table 3: Radiological findings.

338 Table 4: Initial treatment characteristics.

339 FIGURES LEGENDS

340 Figure 1: Clinical severity stratified by gender.

341 Figure 2: CXR's of two different patients showing the most common abnormalities: bilateral,
 342 peripheral ground glass opacities and consolidation

343 Figure 3: Recovery rates stratified by case severity

344 TABLES

345 **Table 2: Patients demographic characteristics at presentation.**

Demographics	All patients (n=150)	Mild cases (n= 105)	Moderate cases (n= 29)	Severe/Intensive care unit cases (n= 16)	P-value
Age (years; mean (SD))	46.1 years (15.3)	45.4 years (±16.0)	46.7 years (±12.1)	49.8 years (±15.7)	0.550
Gender					
Female No. (%)	60 (40.0)	47 (44.8)	10 (34.5)	3 (18.8)	0.112
Healthcare worker					
Yes No. (%)	6 (4.0)	6 (5.8)	0	0	0.110
Place of residency No. (%)					
Kingdom of Saudi Arabia	84 (56.0)	57 (54.3)	15 (51.7)	12 (75.0)	0.084
Other countries	66 (44.0)	48 (45.7)	14 (48.3)	4 (25.0)	0.239
Comorbidities No. (%)					

Hypertension	42 (28.8)	29 (27.6)	10 (35.7)	3 (23.1)	0.627
Diabetes mellitus	38 (26.0)	20 (19.0)	11 (39.3)	7 (53.8)	0.005**
Coronary artery disease	11 (7.5)	5 (4.8)	3 (10.7)	3 (23.1)	0.094
Renal disease	10 (6.8)	5 (4.8)	1 (3.6)	4 (30.8)	0.018*
Thyroid gland problem (hypothyroidism)	9	4 (8.2)	2 (11.1)	3 (37.5)	0.123
Asthma	4 (2.7)	3 (2.9)	0	1 (7.7)	0.306
Cancer	2 (1.4)	0	0	2 (15.4)	0.007**
CVA	1 (0.7)	1 (1.0)	0	0	0.718
COPD	1 (0.7)	0	0	1 (7.7)	0.086
CLD	1 (0.7)	0	0	1 (7.7)	0.086
Tracing history No. (%)					
Recent travel history (Yes) No. (%)	65 (43.9)	47 (45.6)	14 (48.3)	4 (25.0)	0.263
Contact with traveller (Yes) No. (%)	80 (54.1)	57 (55.3)	18 (62.1)	5 (31.3)	0.124
Contact with COVID-19 patient (Yes) No. (%)	96 (64.4)	71 (68.3)	20 (69.0)	5 (31.3)	0.013*
Outcome (n= 148) No. (%)					
Deceased	4 (2.7)	2 (1.9)	0	2 (12.5)	0.086
Improved	47 (31.8)	37 (35.2)	6 (22.2)	4 (25.0)	0.358
Not recovered	3 (2.0)	2 (1.9)	1 (3.7)	0	0.615
Recovered	94 (63.5)	64 (61.0)	20 (74.1)	10 (62.5)	0.434

346 Abbreviations; COVID-19: coronavirus disease-2019; CVA: cerebrovascular accident; COPD: chronic

347 obstructive pulmonary disease; CLD: chronic liver disease; SD: Standard deviation; No: Number (frequency)

348 **Table 2: Patient signs and symptoms at presentation and during admission.**

Variable	Symptoms		P-vale
	At presentation No. (%)	During admission No. (%)	
Fever	72 (49.3)	28 (19.2)	0.029*
Cough	71 (48.6)	28 (19.2)	0.024*
Shortness of breath	29 (19.9)	7 (4.8)	0.000***
Sore throat	24 (16.4)	2 (1.4)	0.269
Runny nose	9 (6.2)	0 (0.0)	>0.99
Sputum	5 (3.4)	1 (0.7)	0.034*
Headache	4 (2.7)	0 (0.0)	>0.99
Myalgia	4 (2.7)	1 (0.7)	0.813
Diarrhea	2 (1.4)	5 (3.4)	0.068
Nausea/vomiting	1 (0.4)	12 (8.2)	0.678
Haemoptysis	1 (0.4)	1 (0.7)	0.887
Fatigue	1 (0.4)	1 (0.7)	0.907

349 * p<0.05; **p<0.01; ***p<0.000

350 **Table 3: Radiological findings.**

Radiological findings (CXR) upon admission					
	All patients (n=150)	Mild cases (n= 105)	Moderate cases (n= 29)	Severe/Intensive care unit cases (n= 16)	P-value
Predominant finding					
Normal	72 (49.7)	62 (60.2)	7 (25.9)	3 (20.0)	0.000***
Ground glass opacity	42 (29.0)	21 (20.4)	13 (48.1)	8 (53.3)	0.002*
Consolidation	26 (17.9)	16 (15.5)	6 (22.2)	4 (26.7)	0.488
Linear atelectasis	3 (2.1)	3 (2.9)	0	0	0.354
Diffusion reticular opacities	1 (0.7)	1 (1.0)	0	0	0.795
Reticulation	1 (0.7)	0	1	0	0.183

Distribution within the lobe					
Central	10 (13.7)	6 (14.6)	2 (10.0)	2 (16.7)	0.833
Diffuse	21 (28.8)	14 (34.1)	4 (20.0)	3 (25.0)	0.494
Peripheral	42 (57.5)	21 (51.2)	14 (70.0)	7 (58.3)	0.378
Distribution within the lung					
Lower	24 (32.9)	12 (29.3)	6 (30.0)	6 (50.0)	0.385
Lower middle	22 (30.1)	10 (24.4)	9 (45.0)	3 (25.0)	0.236
Lower and middle and upper	10 (13.7)	8 (19.5)	2 (10.0)	0	0.089
Diffuse	10 (13.7)	6 (14.6)	2 (10.0)	2 (16.7)	0.833
Peripheral	2 (2.7)	2 (4.9)	0	0	0.309
Middle	2 (2.7)	2 (4.9)	0	0	0.309
Upper	1 (1.4)	1 (2.4)	0	0	0.559
Upper and middle	1 (1.4)	0	0	1 (8.3)	0.159
No zonal predominance	1 (1.4)	0	1 (5.0)	0	0.269
Laterality					
Bilateral	53 (35.3)	27 (25.7)	16 (55.2)	10 (62.5)	0.000***
Unilateral right	12 (16.4)	10 (24.4)	2 (10.0)	0	0.035*
Unilateral left	8 (11.0)	4 (9.8)	2 (10.0)	2 (16.7)	0.805
Progression					
Stable	62 (64.6)	49 (74.2)	11 (57.9)	2 (18.2)	0.001**
Worsen	34 (35.4)	17 (25.8)	8 (42.1)	9 (81.8)	


351 CXR: chest x-ray

352 **Table 4: Initial treatment characteristics.**

Treatment therapy	Frequency (%)
Antiviral therapy	
Combination of antiretroviral (lopinavir and ritonavir) and ribavirin	14 (9.3)
Antimalarial therapy	
Hydroxychloroquine	25 (16.7)
Chloroquine	15 (10.0)
Antibiotics therapy	58 (38.7)

353

354 **FIGURES**




355

356

357 Figure 1: Clinical severity stratified by gender.


358



359

360 Figure 2: CXR's of two different patients showing the most common abnormalities: bilateral,
361 peripheral ground glass opacities and consolidation

362



363

364

365 Figure 3: Recovery rates stratified by case severity